At the cutting edge of Cell and Gene therapy and a centre of excellence for the production of plasmids and non-viral solutions for genetic modifications, Anemocyte will be a key player at the leading sector event thanks to its expertise, dynamism and industrial cell and plasmid manufacturing facilities.
Plasmid
Anemocyte is the leading Italian producer of gene therapy plasmids and is one of the first of its kind in Europe. Having recently built a brand new Plasmid Manufacturing Unit – which is dedicated to producing plasmids for viral vectors – Anemocyte is equipped with state-of-the-art laboratories and facilities, having tripled its production output since 2018. The company’s improved production capacity makes it the perfect partner for researching, developing and producing R&D, High Quality and GMP plasmids, from pre-clinical and clinical phases to commercial production.“In a market where production wait times are extremely long, Anemocyte is able to respond to biopharma company requests quickly and with the highest quality standards,” states Stefano Baila, Director of Operations and Business Development at Anemocyte. “ And it’s all because Anemocyte is a dynamic market player equipped with cutting-edge technologies and over ten years of expertise producing recombinant proteins; experience that it now exploits to produce plasmids – our core business. Pioneering production plants, scrupulous quality control systems, single-use technologies, cross-cutting skills and a flexible production system make us a dynamic enterprise able to intercept market needs and offer punctual, effective and qualitatively competitive results.”
Following a strategic agreement with MaxCyte. Inc., Anemocyte is now a centre of excellence for electroporation technology and can support non-viral gene modification projects requiring both process development and GMP production.
In recent years, the ability to modify cells genetically has exponentially increased the clinical use of cell-based medicines. Non-viral gene modification is an emerging trend in the delivery of nucleic acids to cells thanks to its reliability, safety and affordability with regard to modified gene therapies. Within this context, electroporation technology is at the forefront of non-viral gene transfer for ex-vivo cell modifications.
Anemocyte and MaxCyte. Inc’s agreement includes the construction of a global non-viral gene transfer hub and will see product developers (such as biotechnology companies and academic groups) exploit Anemocyte’s experience and MaxCyte’s technology to assess proof of concept as part of a free licence arrangement.
Announced at last year’s Phacilitate Leaders World, Exellula is Italy’s first industrial centre dedicated entirely to developing and producing Cell and Gene Therapies for third parties.
The first phase of Exellula construction has already begun following the redevelopment of Anemocyte’s headquarters at Gerenzano BioPark Insubrias in Varese. Such initial work led to the creation of the already up and running Anemocyte’s brand new plasmids production unit.
Anemocyte continues to expand its FLYn’ICE project with the aim of meeting growing demand for temperature-controlled logistics in the CGTs sector. Launched in collaboration with RPS Aerospace SRL, the project aims to use special drones to transport drugs under controlled temperature conditions from manufacturing sites to clinical centres for experimentation and treatment activities.
This mode of transport will help to move materials (such as blood, apheresis and biopsies) and innovative drugs to production sites in optimal conditions and as quickly and safely as possible.
